The US Food and Drug Administration (FDA) has granted priority review to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations after complete disease resection.
Publications
New Dissertation on the Treatment of Malignant Melanoma
Malignant melanoma is one of the most common causes of cancer deaths among young adults.
Melanoma Journal Articles for November 2017
The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts.
FDA Accepts sBLA for Nivolumab in Resected, High-Risk, Advanced Melanoma
On October 16, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.